Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword?

Balakumar P, Mahadevan N.

Br J Pharmacol. 2012 Jan;165(2):373-9. doi: 10.1111/j.1476-5381.2011.01597.x. Review.

2.

Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?

Balakumar P, Kathuria S, Taneja G, Kalra S, Mahadevan N.

J Mol Cell Cardiol. 2012 Jan;52(1):83-92. doi: 10.1016/j.yjmcc.2011.09.014. Epub 2011 Sep 24. Review.

PMID:
21968328
3.

Perspectives on the cardioprotective effects of statins.

Luo JD, Chen AF.

Curr Med Chem. 2003 Aug;10(16):1593-601. Review.

PMID:
12871130
4.

Beneficial cardiovascular pleiotropic effects of statins.

Davignon J.

Circulation. 2004 Jun 15;109(23 Suppl 1):III39-43. Review.

5.

Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.

Pedersen TR.

Am J Cardiovasc Drugs. 2010;10 Suppl 1:10-7. doi: 10.2165/1158822-S0-000000000-00000. Review.

PMID:
21391729
6.

Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy.

Zhou Q, Liao JK.

Curr Pharm Des. 2009;15(5):467-78. Review.

7.

Effects of statin therapy on the progression of chronic kidney disease.

Shah S, Paparello J, Danesh FR.

Adv Chronic Kidney Dis. 2005 Apr;12(2):187-95. Review.

PMID:
15822054
8.

Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms.

Paumelle R, Staels B.

Trends Cardiovasc Med. 2008 Apr;18(3):73-8. doi: 10.1016/j.tcm.2008.01.001. Review.

PMID:
18436144
9.

Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.

Danesh FR, Kanwar YS.

FASEB J. 2004 May;18(7):805-15. Review.

PMID:
15117885
10.

The evolving role of statins in the management of atherosclerosis.

Vaughan CJ, Gotto AM Jr, Basson CT.

J Am Coll Cardiol. 2000 Jan;35(1):1-10. Review.

11.

Statins: a new insight into their mechanisms of action and consequent pleiotropic effects.

Jasińska M, Owczarek J, Orszulak-Michalak D.

Pharmacol Rep. 2007 Sep-Oct;59(5):483-99. Review.

12.
13.

Statin therapy-evidence beyond lipid lowering contributing to plaque stability.

de Lorenzo F, Feher M, Martin J, Collot-Teixeira S, Dotsenko O, McGregor JL.

Curr Med Chem. 2006;13(28):3385-93. Review.

PMID:
17168712
14.

Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins.

Lahera V, Goicoechea M, de Vinuesa SG, Miana M, de las Heras N, Cachofeiro V, Luño J.

Curr Med Chem. 2007;14(2):243-8. Review.

PMID:
17266583
15.

Pleiotropic effects of HMG-CoA reductase inhibitors.

Werner N, Nickenig G, Laufs U.

Basic Res Cardiol. 2002 Mar;97(2):105-16. Review.

PMID:
12002257
16.

Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering.

Marzilli M.

Am J Cardiovasc Drugs. 2010;10 Suppl 1:3-9. doi: 10.2165/1153644-S0-000000000-00000. Review.

PMID:
21391728
17.

Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction.

Ito MK, Talbert RL, Tsimikas S.

Pharmacotherapy. 2006 Jul;26(7 Pt 2):85S-97S; discussion 98S-101S; quiz 106S-108S. Review.

PMID:
16803418
19.

Pleiotropic effects of HMG-CoA reductase inhibitors.

Bocan TM.

Curr Opin Investig Drugs. 2002 Sep;3(9):1312-7. Review.

PMID:
12498006
20.

Beyond lipid lowering: the role of statins in vascular protection.

Liao JK.

Int J Cardiol. 2002 Nov;86(1):5-18. Review.

PMID:
12243846

Supplemental Content

Support Center